Items where authors include "Schlichting, DE"

Article

Peterfy, C, DiCarlo, J, Emery, P orcid.org/0000-0002-7429-8482 et al. (7 more authors) (2019) Use of Magnetic Resonance Imaging to Support Dose Selection in a Phase II Trial of Baricitinib Combined with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. Journal of Rheumatology, 46 (8). pp. 887-895. ISSN 0315-162X

Taylor, PC, Lee, YC, Fleischmann, R et al. (12 more authors) (2019) Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial. Journal of Clinical Medicine, 8 (6). 831. ISSN 2077-0383

Tanaka, Y, McInnes, IB, Taylor, PC et al. (10 more authors) (2018) Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis. Arthritis & Rheumatology, 70 (12). pp. 1923-1932. ISSN 2326-5191

Tanaka, Y, McInnes, IB, Taylor, PC et al. (10 more authors) (2018) Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis. Arthritis and Rheumatology, 70 (12). pp. 1923-1932. ISSN 2326-5191

Taylor, PC, Kremer, JM, Emery, P et al. (14 more authors) (2018) Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Annals of the Rheumatic Diseases, 77 (7). pp. 988-995. ISSN 0003-4967

van der Heijde, D, Dougados, M, Chen, Y-C et al. (10 more authors) (2018) Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open, 4 (1). e000662. ISSN 2056-5933